Grant Glues Together Research Experts To Tackle Incurable Diseases (UF Scripps)
UF researcher Thomas Kodadek’s team has won a prestigious international grant to collaborate with Merck KGaA on developing “molecular glue degraders,” a novel technology that harnesses the body’s recycling system to treat previously undruggable diseases like aggressive cancers and brain disorders.
Scientists Say These Two Viruses May Become the Next Public Health Threats (UF Health)
A study co-authored by UF’s Dr. John Lednicky identifies influenza D and canine coronavirus as emerging respiratory threats, citing a critical need for UF-led surveillance to prevent potential spillover events.
LightPath Technologies Acquires Amorphous Materials, Inc. (PR Newswire)
UF startup LightPath Technologies, Inc. announced it has acquired the assets of Amorphous Materials, Inc., which is an industrial manufacturer with complementary Chalcogenide glass melting technologies.
Genezen and Atsena Therapeutics Announce Strategic Commercial Manufacturing Partnership (PR Newswire)
UF startup Atsena Therapeutics and Genezen announced a manufacturing partnership to support the clinical development and future production of Atsena’s gene therapies for inherited retinal diseases.
Neuropacs Closes Seed Round of Financing (Businesswire)
UF startup neuropacs™ Corp. announced the successful raise of over $1.0 million in early-stage capital.
Alachua County’s Bystander CPR Rates Save Lives, Study Finds (UF Health)
A study UF researchers published in the Journal of Clinical Medicine shows that following the local activation of PulsePoint, an app that alerts CPR-trained individuals about a nearby cardiac event, rates of bystander CPR performed outside a hospital setting significantly increased in Alachua County.
Solid Biosciences Doses First Patient in Phase 1b FALCON Trial for Friedreich’s Ataxia (Solid Biosciences)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-human clinical trial evaluating SGT-212, its investigational gene therapy for the treatment of Friedreich’s ataxia (FA).
UF/IFAS Awards $321K in AI Grants To Advance Ag-Tech Industry (UF/IFAS)
Five UF research teams were selected as recipients of the 2026 Launching Innovative Faculty Teams in AI funding program to advance AI research in agriculture.
Atsena Completes Part B Dosing and Advances to Pivotal Part C of LIGHTHOUSE Trial (Atsena Therapeutics)
UF startup Atsena Therapeutics announced that dosing is complete in patients enrolled across all adult and pediatric cohorts in Part B of the Phase I/II/III Lighthouse Trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Researchers Find Vital Clue in the Progression of Type 1 Diabetes (UF Health)
UF researchers have added an important piece to the puzzle in understanding the progression of type 1 diabetes.